Edition:
United Kingdom

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

95.50USD
7:39pm BST
Change (% chg)

$-0.08 (-0.08%)
Prev Close
$95.58
Open
$95.00
Day's High
$96.86
Day's Low
$94.33
Volume
347,168
Avg. Vol
497,829
52-wk High
$100.00
52-wk Low
$75.84

Chart for

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $16,617.19
Shares Outstanding(Mil.): 175.27
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -1.02 -- --
ROI: -5.48 14.84 14.38
ROE: -7.41 16.34 16.07

S&P, Dow fall as oil drop hurts energy; chipmakers boost Nasdaq

NEW YORK The S&P 500 and the Dow eased on Friday after a steep drop in oil prices pressured energy stocks, but losses were limited by gains in chipmakers and retail stocks.

25 May 2018

FDA approves BioMarin rare metabolic disorder drug, shares rise

U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

25 May 2018

FDA approves BioMarin rare metabolic disorder drug, shares rise

May 24 U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

25 May 2018

BRIEF-Biomarin Pharmaceutical Q1 GAAP Loss Per Share $0.26

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

25 Apr 2018

BRIEF-Biomarin Pharmaceutical Reports Q1 Loss Per Share Of $0.25

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

25 Apr 2018

BRIEF-Biomarin Pharma CEO's 2017 Compensation Was $15.9 Million

* BIOMARIN PHARMACEUTICAL INC SAYS CEO JEAN-JACQUES BIENAIMÉ'S 2017 TOTAL COMPENSATION WAS $15.9 MILLION VERSUS $16.9 MILLION IN 2016 – SEC FILING

24 Apr 2018

BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase

* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARIN'S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)

28 Mar 2018

BRIEF-BioMarin Q4 GAAP Loss Per Share $0.30

* BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

22 Feb 2018

BRIEF-Biomarin Receives Anticipated Notification Of PDUFA Extension For Pegvaliase Biologics License Application

* BIOMARIN RECEIVES ANTICIPATED NOTIFICATION OF PDUFA EXTENSION FOR PEGVALIASE BIOLOGICS LICENSE APPLICATION (BLA) TO MAY 28, 2018

22 Dec 2017

BRIEF-Biomarin Doses First Patient In Late-Stage Trial Of Gene Therapy For Bleeding Disorder

* BIOMARIN DOSES FIRST PATIENT IN GLOBAL GENER8-1 PHASE 3 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A Source text for Eikon: Further company coverage:

19 Dec 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.55 +1.23
Pfizer Inc. (PFE.N) $36.22 +0.06
Novartis AG (NOVN.S) CHF75.60 +0.10
Merck & Co., Inc. (MRK.N) $60.91 -0.08
Roche Holding Ltd. (ROG.S) CHF211.05 +1.05
Roche Holding Ltd. (RO.S) CHF216.80 +2.40
Abbott Laboratories (ABT.N) $62.21 -0.61
Bayer AG (BAYGn.DE) €96.63 -1.83
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €67.67 -0.58

Earnings vs. Estimates